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3, 3’, 5, 5’-Tetramethybenzindine    TMB 
Ak strain transforming     AKT 
Arg-Gly-Gly       RGG 
Ataxia telangiectasia mutated     ATM 
Basal Cell Carcinoma      BCC 
B-cell lymphoma/leukemia 2     BCL-2 
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MicroRNA       miRNA 
Mouse double minute 2     MDM2 
Mre11-Rad50-Nbs1      MRN 
Non-Melanoma Skin Cancer     NMSC 
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Non-Transfected      NT 
Nucleolin       NCL 
Nucleotide       nt 
Phosphatase and Tensin Homologue    PTEN 
Precursor microRNA      pre-miRNA 
Primary microRNA      pri-miRNA 
Ribosomal RNA      rRNA 
RNA-Binding Domain     RBD 
RNA Induced Silencing Complex    RISC 
RNA Recognition Motif     RRM 
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Squamous Cell Carcinoma     SCC 
Standard Deviation      SD 
Tris phosphate buffered saline    TPBS 
Ultra-Violet Radiation     UVR 
Ultra-Violet A       UVA 
Ultra-Violet B       UVB 
Ultra-Violet C       UVC 
Variable Heavy      VH 
Variable Light       VL 




Skin cancer is the most frequently diagnosed malignancy in the United States, and the more 
aggressive forms suffer from limited or ineffective treatment options.  These cancers are 
commonly caused by damage to the DNA from exposure to UV-radiation via sunlight.  In these 
cancers, nucleolin (NCL) is frequently found overexpressed and localized to the cell surface, 
however, little is known about the mechanism of NCL upregulation in cancer cells.  NCL is 
involved in the regulation of the biogenesis of a specific set of oncogenic microRNAs, including 
miR-21, -221, and -222, which contribute to cell survival and proliferation and are also found 
overexpressed in skin cancers.  Targeting surface NCL has shown promise as a potential therapy 
for several cancers, and for this reason, we developed a single chain variable fragment, called 
4LB5, which binds NCL with high affinity and inhibits its microRNA processing abilities in breast 
cancer cell lines. 
This study aimed to determine a mechanism of NCL overexpression in skin cancer and 
validate the use of 4LB5 as a tool for skin cancer therapy.  First, we investigated the regulation of 
NCL by microRNAs, because these molecules have been widely implicated in the regulation of 
proteins important to the development of cancers.  Direct targeting of NCL by miR-203 was 
demonstrated through luciferase assays and miR-203 transfections.  To further understand this 
regulatory mechanism and to link NCL expression to the primary cause of skin cancer, DNA 
damage, we investigated the regulation of miR-203 by p53.  P53 is a crucial player in the cellular 
response to stress and functions to maintain genomic integrity by regulating DNA repair, cell cycle 
progression, and apoptosis.  Additionally, it is one of the most frequently mutated genes in cancer.  
When exposed to UV-radiation, skin cancer cell lines increased p53 expression, and we observed 
a corresponding rise in miR-203 levels.  Conversely, knockdown of p53 through transfection with 
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si-p53 led to a reduction in miR-203.  From this, we propose that NCL expression is, in part, 
regulated by p53 via miR-203.  When p53 is inactivated or mutated, expression of miR-203 is 
impaired leading to excessive NCL production.   
By treating skin cancer cells with 4LB5, we hypothesized that we could reduce cellular 
proliferation by counteracting the upregulation of NCL.  Through ELISA, we showed that 4LB5 
specifically binds to cell surface NCL in skin cancer cell lines.  To confirm that 4LB5 had 
antineoplastic effects in skin cancer, we first assessed the effect of 4LB5 treatment on the NCL-
associated microRNAs, miR-21, -221, and -222.  Through Real-Time PCR we demonstrated that 
4LB5 treatment resulted in reduced levels of all three microRNAs.  Western blot confirmed that 
down-regulation of these microRNAs resulted in an upregulation of the tumor suppressor PTEN 
and a decrease in activated AKT.  Finally, by alamarBlue and colony assay, we observed a 
reduction in cellular proliferation in treated melanoma cell lines. 
In summary, here we uncovered an unknown mechanism in skin cancer that is responsible, 
at least in part, for the upregulation of NCL seen in these malignancies and provided support for 










Skin Cancer.  Skin cancers account for most cancer diagnoses in the United States and represent 
a significant and increasing burden on the health care system.  It is estimated that in the United 
States one in five people will develop skin cancer.  From 2002 to 2011, the average annual total 
cost associated with skin cancer rose $4.5 billion dollars, an increase in cost of 126.2% (1).  During 
the same period, the cost for all other cancers increased 
by only 25.1% (1).  Rates of skin cancer diagnosis 
increase significantly with age, reflecting a long 
separation between exposure to a carcinogen and the 
onset of cancer.   
Skin cancers are divided into categories based 
on clinical behavior and the cells from which the 
malignancy originates.  The two major groups are non-
melanoma skin cancers (NMSC) which arise from 
keratinocytes - the predominant cells in the epidermis 
- and cutaneous malignant melanomas which form 
from the melanocytes - the pigment producing cells of skin and hair (Fig. 1) (2). 
NMSCs account for the vast majority of skin cancer diagnoses, with about 1.3 million cases 
reported in the U.S. each year (3), and the rate of diagnosis is expected to double in the next 30 
years (4).  While common, NMSCs have a good long-term prognosis due in part to the tendency 
of these malignancies to remain within the primary disease site.  The two main forms of NMSC 
are basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).  Accounting for roughly 80% 
of all NMSCs and 30% of all cancer diagnoses (3), BCCs typically arises from the basal layer of 
Figure 1.  Keratinocytes and melanocytes in the skin.  
Keratinocytes are the predominant cells in the epidermis.  
The basal layer of the epidermis is comprised of basal cells 
which constantly divide to replace dead and damaged 
keratinocytes in the upper layers (6).  Melanocytes, the 
melanin pigment producing cells, also reside in the basal 
layer.  These cells deliver melanin to keratinocytes through 





the epidermis (2).  These tumors are most frequently found on areas of the body that undergo 
constant sun exposure, such as the head and neck, but can also form on the trunk and extremities 
(2).  BCC is rarely fatal and because of its low risk of metastasis, treatment through surgery is 
generally sufficient to remove the malignancy (2).  SCCs account for roughly 16% of all skin 
cancers and are considered the second most common form of skin cancer (2).  These tumors are 
more aggressive than BCCs, more likely to metastasize, and account for most NMSC-related 
metastatic disease and death (5).  Additionally, SCC is considered one of the top five most costly 
cancers in the US with incidence expected to rise in the future due to increasing sun exposure, age, 
and public awareness of skin cancer (5).   
 Cutaneous malignant melanoma, accounts for only 4% of skin cancer diagnoses, but is 
responsible for roughly 75% of skin cancer related fatalities (2).  In 2010, about 68,000 new cases 
of melanoma were diagnosed, and in the same year, 8,700 deaths were attributable to melanoma 
in the United States.  When detected early, surgical excision alone can be sufficient to remove the 
malignancy, however, in the case of advanced disease, long-term prognosis is poor due to the fast 
invading and metastasis prone nature of these tumors (6).    
 Risk factors for melanoma include fair pigmentation, poor tanning ability, multiple nevi, 
clinically atypical nevi, dysplastic nevi, and freckling (6, 7, 8).  One of the greatest risk factors for 
the development of skin cancer is exposure to ultra-violet radiation (UVR) via sunlight (6).  
Through direct and indirect mechanisms, such as gene mutation, formation of pyrimidine dimers, 
immunosuppression, and oxidative stress, UVR is able to damage skin cells (3).  UVR is divided 
into three types based on wavelength and energy: ultraviolet A [UVA (315-400 nm)], ultraviolet 
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B [UVB (280-135 nm)], and ultraviolet C [UVC (100-280 nm)].  As shown in Fig 2, UVR 
distribution in the skin varies with type and depth.  UVA radiation accounts for 90-99% of all 
UVR that reaches the Earth’s surface and contributes to 
skin aging and tanning.  Excessive and long-term 
exposure to UVA is believed to be harmful (3) and an 
important factors in the development of melanoma (9, 
10).  UVB accounts for 1-10% of UVR and is responsible 
for causing sunburns, wrinkling, tanning, and NMSCs.  
Often, UVB can create mutations in the p53 gene, a 
transcription factor involved in DNA repair and cellular 
apoptosis, which leads to dysregulation of these 
processes and the initiation of skin cancer (11). 
 
P53. P53 was first classified as an oncogene, but later work determined that wild-type p53, 
encoded by the TP53 gene, suppressed growth and oncogenic transformation of cells in culture 
(12).  Since its initial discovery, p53 has become known as the ‘guardian of the genome’ because 
of its critical roles in DNA repair and damage related cell death.  As a DNA binding protein, p53 
functions as a transcription factor to regulate the expression of target genes at the transcriptional 
level (13).  In response to cellular stress, p53 is activated to regulate a wide range of pathways and 
processes to maintain genomic integrity and prevent tumorigenesis.  P53 is comprised of two N-
terminal transactivation domains followed by a conserved proline-rich domain, a central DNA 
binding domain, and a C-terminus containing a nuclear localization signal.  For transcriptional 
Figure 2.  Penetration of UV radiation in the skin.  
Of the UVR to reach the Earth’s surface, 90% is 
UVA while only about 10% is UVB.  UVA light 
reaches the deeper layers of the skin and is believed 
to be important in the development of melanoma. 
UVB light can cause DNA damage in the form of 




activity, p53 contains an oligomerization domain (12).  The majority of mutations to p53 found in 
tumors are to the DNA binding domain encoding region of TP53 (13, 14).     
In the absence of cellular stress, p53 protein levels are kept low by interaction with the E3-
ubiquitin protein ligase MDM2.  This binding leads to the proteasome-mediated degradation of 
p53 in the cytoplasm (13, 15).  In response to cellular stress, p53 and MDM2 undergo post-
translational modifications dependent on the stress type by a variety of enzymes.  Specifically in 
response to DNA damage, p53 is phosphorylated by ATM resulting in the stabilization of p53 and 
its release from MDM2 (16).  Once activated, p53 forms a quadraplex that regulates the expression 
of target genes by binding in a sequence specific manner to DNA which allows it to modulate 
cellular processes including cell cycle arrest, apoptosis, senescence, and DNA repair.  Some of 
these process are summarized in Fig. 3. 
 
 TP53 is one of the most commonly mutated genes in human cancers.  In skin cancer 
specifically, inactivating mutations to p53 are common, and UV-induced mutations to TP53 have 
been implicated as an important step in the development of these cancers.  TP53 mutations are 
present in the majority of NMSCs (90% in SCC and 50% in BCC) (17).  The majority of p53 
Figure 3.  P53 functions as a tumor-suppressor in multiple cellular pathways.  In the 
absence of cellular stress, interactions with MDM2 keep p53 levels low.  When under 
stress, p53 is activated and released from MDM2 via post-translational modifications.  In 
its active form, p53 regulates the expression of numerous genes involved in cellular 
processes including apoptosis, cell cycle arrest, and senescence. (13) 
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mutations in cancer are missense mutations which result in the expression of a full length mutant 
protein (13).  When wild-type and mutant p53 are present in the same cell, mutant p53 can 
inactivate the wild-type protein through a dominant negative effect (18), but often, p53 mutations 
are followed by a loss of heterozygosity in the tumor leading to a complete absence of wild-type 
p53 (13).  In some cases, p53 mutants gain new oncogenic functions in the cell.  For instance, 
mutant p53 can regulate the expression of specific microRNAs, short RNA molecules involved in 
the regulation of gene expression, leading to new oncogenic functions.  In endometrial cancer, 
mutant p53 can directly interact with the miR-130b promotor and inhibit its transcription leading 
to the promotion of the epithelial-mesenchymal transition and cancer cell invasion (19).  In breast 
cancer, mutant p53 induces miR-155 expression which drives the invasion of cancer cells (20).  
Mutant p53 has also been shown to interact with Drosha to inhibit the processing of certain primary 
microRNAs (21).   
 
Nucleolin.  Nucleolin (NCL) is one of the most abundant nucleolar proteins, accounting for as 
much as 10% of total protein in the nucleolus (22).  While its predicted molecular mass is 77 kDa, 
NCL is described as a 100-110 kDa protein due to the amino acid composition of the N-terminus 
and the addition of post-translational modifications (22).  NCL is composed of three major 
domains: the N-terminal domain, the RNA binding domains, and the GAR region (Fig. 4A).  The 
N-terminal domain is composed of highly acidic regions separated by basic sequences that allow 
the protein to interact with histone H1 and modulate DNA condensation in chromatin (23, 24, 25).  
This region is also involved in protein-protein interactions with ribosomal proteins.  The N-
terminus is highly phosphorylated by kinases like the casein kinase 2 (CK2) which probably 
regulates NCL function during the cell cycle (22).  The central region of NCL is composed of 
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RNA-binding domains (RBDs).  In 
animal cells, NCL contains 4 RBDs while 
yeast and plant NCL contains 2 RBDs 
(23).  Through the RNA recognition 
motifs (RRMs) in the RBDs, NCL 
interacts with the stem loop structure of 
RNA to participate in the modification 
and processing of pre-ribosomal RNA 
(23).  The third domain, the GAR (or 
RGG) domain is a region rich in 
Arginine-Glycine repeats in the order 
Arg-Gly-Gly (22).  This region functions 
in protein-protein interactions and has been implicated in ribosomal assembly and nuclear import 
of ribosomal proteins (23, 26). 
 The majority of NCL is located within the nucleolus, but it is also present in other nuclear 
regions, the cytoplasm, and on the plasma membrane (Fig. 4B) (27), however, where and how 
NCL is incorporated on the membrane is unclear.  The principal function of NCL is ribosomal 
RNA (rRNA) processing and ribosome biogenesis where it plays key roles in rRNA transcription, 
rRNA maturation, and ribosome assembly (22, 23, 27).  In addition to its function in ribosome 
biogenesis, NCL has been implicated in numerous other biological processes throughout the cell.  
Roles for NCL have been established in DNA metabolism where it affects DNA replication, repair, 
recombination, telomere maintenance, and chromatin remodeling.  During the DNA damage 
response, NCL has been shown to co-localize with sites of DNA double strand breaks and interact 
Figure 4.  Structure and localization of NCL.  (A)  Nucleolin is 
composed of three major domains:  the N-terminus, centrally located 
RNA binding domains, and the glycine and arginine rich GAR domain.  
(B)  The majority of NCL is located within the nucleolus, but NCL is 
also found throughout all the major cellular compartments.  Percentages 
indicate the fraction of total NCL found in each compartment.  In cancer 
cells, NCL is found on the cell surface, however, where and how it is 
incorporated is unknown.  Adapted from (87) 
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with Rad50 and the MRN complex to facilitate H2A-H2B removal at transcription loci (28, 29, 
30).  In response to UV-induced DNA damage, NCL has been shown to interact with proteins 
involved in nucleotide excision repair (30).  NCL is involved in nucleocytoplasmic transport, likely 
moving newly assembled ribosomal subunits into the cytoplasm.  The stability and translation of 
specific subsets of mRNAs can be affected by NCL through interactions with AU-rich elements 
in the 5’-UTR or through interactions with G-rich sequences throughout the 5’-UTR, coding 
region, or 3’-UTR.  NCL can either increase or decrease the half-life of mRNA through 
interactions with the UTRs of target molecules.  Bcl-2 mRNA which encodes the anti-apoptotic 
and pro-oncogenic protein BCL-2, is stabilized by NCL through an interaction between the protein 
and the AU-rich elements in the mRNA (31, 32).  By binding with the 5’-UTR of TP53 mRNA, 
NCL can inhibit the induction of p53 in response to DNA damage (33).  NCL also regulates the 
biogenesis of a specific subset of microRNA molecules through interactions with the 
microprocessor complex (34). 
 
MicroRNAs.  MicroRNAs (miRNAs) are small, noncoding RNA molecules of about 22 nt that 
function as regulatory elements by base pairing with sequences in mRNA molecules (35).  The 
first miRNA, lin-4, was discovered in Caenorhabditis elegans over 30 years ago (36).  Since their 
initial discovery, miRNAs have been implicated in numerous human diseases.  Gene expression 
and profiling studies have revealed that miRNAs are frequently dysregulated in human diseases, 
and in several cancer types alterations in miRNA expression patterns have been identified. 
All miRNAs undergo a biogenesis process that converts the primary miRNA transcript into 
the mature, functional miRNA (Fig. 5).  This process begins with the transcription of a miRNA 
gene.  These genes are located throughout the genome and may be incorporated into an intron or 
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untranslated region of a protein coding gene or 
present as an independent gene (35).  
Transcription of a miRNA gene by RNA 
polymerase II results in a primary miRNA (pri-
miRNA) transcript with a stem-loop precursor 
RNA structure (37).  Generally, the pri-miRNA 
is spliced, capped, and polyadenylated in a 
manner similar to protein coding mRNAs.  The 
first endonuclease processing step occurs 
during or subsequent to transcription and is 
carried out by the enzyme Drosha and its 
associated RNA binding protein DGCR8 which 
is required for cleavage of the pri-miRNA (38, 
39, 40).  Cleavage by Drosha releases the stem-
loop precursor from the pri-miRNA transcript 
sequences to form the precursor miRNA (pre-
miRNA) (41).  The pre-miRNA is exported out of the nucleus by Exportin5 in a Ran-GTP 
dependent manner (42).  In the cytoplasm, the second processing step is completed by Dicer, an 
endonuclease, which cleaves the loop region of the pre-miRNA to release the mature miRNA in a 
duplex form of about 21 nt (43, 44).  One strand of the duplex is loaded into the RNA induced 
silencing complex (RISC) while the other strand, denoted as the star strand, is typically degraded 
(45, 46).  However, some star strands are loaded into the RISC at a similar frequency as the mature 
miRNA.  In these cases, the strand from the 5’ end is labeled 5p and the strand from the 3’ end is 
Figure 5.  MicroRNA processing.  In the nucleus, a miRNA gene is 
transcribed by RNA polymerase II/III resulting in a primary-miRNA 
(pri-miRNA) transcript containing a precursor stem loop structure.  The 
stem-loop precursor (pre-miRNA) is released after cleavage by the 
microprocessor complex.  In the biogenesis of specific miRNAs, NCL 
interacts with this complex to regulate miRNA processing.  The pre-
miRNA is exported into the cytoplasm where further processing by 
Dicer and RISC convert the double stranded pre-miRNA into a 22 nt 
mature miRNA. (35) 
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labeled 3p (47).  In the RISC, the protein Argonaute directly binds the mature miRNA which serves 
as a guide to target mRNAs leading to the destabilization and degradation of these mRNAs (47). 
 During miRNA processing, NCL has been reported to interact with the microprocessor 
complex to regulate the biogenesis of a specific subset of miRNAs including miR-21, miR-221, 
and miR-222 (34, 48).  Aberrant expression of miR-21 was first observed in human glioblastoma, 
and it has since been found overexpressed in numerous cancers including breast, colon, lung, 
pancreatic, prostate, stomach, and head and neck cancers (49, 50, 51).  Overexpression of miR-21 
in hepatocellular cancer cells led to an increase in cellular proliferation and migration (52).  
Conversely, inhibition of miR-21 reduced invasion, anchorage-independent colony formation, and 
proliferation in these cells (52, 53).  Additionally, overexpression of miR-21 has been observed in 
melanoma tissues where it is associated with increases in proliferation and decreases in apoptosis 
(54).  Among other proteins, miR-21 regulates the expression of the tumor suppressor protein 
phosphatase and tensin homologue (PTEN) and downstream PI3-kinase signaling (52) leading to 
the activation of AKT (55).  Similar to miR-21, miR-221 and miR-222 are found overexpressed in 
certain cancers, including metastatic melanoma, where increased proliferation and cellular 
migration were observed in cells with enhanced expression of these miRNAs (56).      
 MicroRNA-203 is the most abundant keratinocyte-specific miRNA in the epidermis (57) 
and is required for skin development and differentiation.  It plays an anti-proliferative role in the 
skin by targeting p63, a transcription factor important for maintaining basal keratinocyte 
proliferative potential in the epidermis (58).  Downregulation of miR-203 promotes the epithelial-
mesenchymal transition and enables tumors to acquire metastatic features (59, 60).  In 




Nucleolin Targeting, scFv, and 4LB5.  NCL is an attractive therapeutic target because of its 
oncogenic role and its cancer cell specific localization to the plasma membrane.  Several 
approaches to target cell surface NCL have been explored.  AS1411, a DNA aptamer against NCL, 
was the first nucleolin targeting agent to reach human clinical trials and has shown promise as a 
potential antineoplastic treatment (62).  In phase I and II trials AS1411 showed low toxicity and 
evidence of therapeutic activity, but suffered from a 
low overall response rate among patients (63, 64).  
Other groups have explored targeting NCL through 
peptides (65). 
To target NCL, we have developed 4LB5, a 
fully human single-chain variable fragment (scFv) 
antibody.  ScFvs are small molecules (26-28 kDa), 
derivative of an antibody (66).  They are composed of 
the variable heavy (VH) and variable light (VL) 
domains of an antibody (the complete antigen binding 
site) connected via a short linker peptide (Fig. 6A-B) 
(67).  These molecules bind to their target compounds with a similar affinity as the parent antibody 
(68).   
Our compound, isolated by phage-display, binds with high affinity to the four RNA binding 
domains of NCL and disrupts the interaction between NCL and the miRNAs it regulates (48).  In 
a previous study, 4LB5 was shown to bind to cell surface NCL on triple negative breast cancer 
cells and reduce cell survival and proliferation.  This treatment resulted in decreased levels of miR-
21, miR-221, and miR-222 (48).   
Figure 6. Structure of antibodies and scFvs.  (A) 
Antibodies are heterotetramers composed of two 
identical heavy chains (blue) and two identical light 
chains (purple) joined by disulfide bonds.  Each light 
chain contains a variable domain (dark purple) and 
one constant domain (light purple).  The heavy chains 
also contain one variable (dark blue) and one constant 
(light blue) domain.  (B) Single chain variable 
fragments are 28 kDa proteins composed of the 
variable domains of the light and heavy chains linked 




Goals.  This study aims to identify a regulatory pathway in skin cancer that explains, in part, NCL 
overexpression in skin cancers and validate 4LB5 as a compound for the treatment of these 
malignancies. 
 The specific aims of this study are to: 
1. Investigate the post-transcriptional regulation of NCL 
2. Evaluate 4LB5 as an antineoplastic tool for skin cancer treatment and its 


































Materials and Methods 
 
Cell Cultures.  SKMEL-147, human melanoma cells, and NL-145, murine melanoma cells, were 
provided by Dr. Christin Burd (OSU, Columbus, OH).  SCC-13, human SCC cells, were provided 
by Dr. Amanda Toland (OSU, Columbus OH).  All cell lines were cultured in DMEM with 10% 
(vol/vol) fetal bovine serum (FBS) and penicillin-streptomycin.  Cell lines were cultured in a 
humidified atmosphere containing 5% CO2 at 37℃.   
 
Plasmids and Mutagenesis.  The pcDNA3 flag p53 vector (FLAG-p53) was a gift from Thomas 
Roberts (Addgene plasmid # 10838) (69).  The 3’-UTR of NCL mRNA (nucleotide 6 to nucleotide 
419) containing the predicted miR-203 seed site, was cloned into the luciferase reporter gene 
plasmid psiCheck 2.0 (Promega): For, 5’-GGCCTCTAGAgtccctctgctttccctttt-3’; Rev, 5’-
GGCCCTCAGAatttgtcctaaagccgctga-3’.  The miR-203a-3p binding site (5’-ACATTTCA-3’) was 
removed from the NCL 3’-UTR luciferase reporter plasmid through site directed mutagenesis 
(GENEART Site-Directed Mutagenesis System, Life-Technologies) according to the 
manufacturer’s protocol. 
 
Transfections, miRNAs, and siRNAs.  Transfections were performed using Lipofectamine 2000 
(Life Technologies) as described by the manufacturer.  MiR-203a-3p miRNA (4464066), control 
miRNA (AM17110), TP53 siRNA (AM1331), NCL siRNA (4390824), and control siRNA 
(AM4611) were purchased from Life Technologies.   
 
Luciferase Assay.  In 12-well plates, SKMEL-147 cells were co-transfected with 20 ng of either 
the luciferase reporter plasmid containing the wild-type NCL 3’-UTR (psiCH-Ncl-WT) or the 
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mutated plasmid (psiCH-Ncl-MUT) and 100 nM of either control miRNA or miR-203a-3p.  
Luciferase and Renilla activity were assessed with the Dual-Light Luciferase system (Promega) 
according to the manufacturer’s instructions at 48 h post-transfection.  Luciferase activity was 
normalized to Renilla activity.  All experiments were performed three times in triplicate, and the 
mean ± SD was reported. 
 
Cell ELISA.  1.0 X 104 SKMEL-147 and NL-145 cells were plated in 96-well V-bottomed plates 
and incubated with increasing concentrations of 4LB5 for 2 h while shaking.  Cells were washed 
with TPBS (0.1% Tween in PBS) and PBS before incubation with Penta-His HRP conjugate 
antibody (1000X, 3% BSA in PBS) for 1 h while shaking.  Cells were again washed with TPBS 
and PBS.  TMB was added to each well and the reaction was stopped with the addition of HCl in 
a 1:1 ratio.  Absorbance at 450 nm was read.  All experiments were performed in triplicate, and 
the mean ± SD was reported. 
 
Protein Extraction, Western Blot, and Antibodies.  Proteins were extracted using NIH lysis 
buffer with added phosphatase and protease inhibitors as previously described (48).  Western blots 
were conducted according to standard procedures.  Anti-NCL (D4C70), anti-pAKT (T308), anti-
AKT (9272), and anti-GAPDH (14C10) were purchased from Cell Signaling.  Other antibodies 
used included, anti-PTEN (138G6, Cell Signaling), anti-p53 (DO-1, Santa Cruz Biotechnology), 
anti-vinculin (4650, Cell Signaling), and anti-FLAG (F1806, Sigma). 
 
RNA Extractions and Real-Time PCR.  RNA was extracted using TRI Reagent (Sigma) 
according to the manufacturer’s protocol.  Real-Time PCR was performed as previously described 
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(48).  Simultaneous quantification of RNU6 was used as a reference for miRNA quantification and 
GAPDH mRNA was used as a reference for mRNA quantification.  
 
4LB5 Preparation and Treatments.  4LB5 is a recombinant protein produced from BL21DE3 
E. Coli cells, as previously described (48).  SKMEL-147 and NL-145 cells were control treated or 
treated with 25 nM-400 nM 4LB5 and harvested at different time points.     
 
AlamarBlue and Colony Assay.  AlamarBlue experiments were performed using the alamarBlue 
Cell Viability Reagent (Invitrogen) according to the manufacturer’s protocol on SKMEL-147 cells 
treated with 6.25-400 nM of 4LB5.  For colony assay experiments, 200 SKMEL-147 or NL-145 
cells were plated in 12-well plates with 10-100 nM of 4LB5 for 72 h.  Cells were replenished with 
complete medium without 4LB5 and allowed to grow for 7 days.  Then, cells were fixed with 1% 
glutaraldehyde in PBS and stained with Crystal violet. 
 
UVR Assay.  SKMEL-147 cells were exposed to 1 J/m2 of UVB irradiation.  At 6 h post-exposure, 
cells were collected.  P53 and miR-203 expression were assessed via western blot and Real-Time 
PCR, respectively.  Experiments were performed in duplicate and mean ± SD was reported.  
 
Statistical Analysis.  Student’s t-test was used to determine significance (indicated as p-value).  








MicroRNA-203 downregulates NCL.  Given the known role of miRNAs in tumorigenesis, we 
hypothesized that miRNAs may play a role in regulating NCL expression in skin cancers.  
Computational target predictions were used to identify miRNAs that could potentially target the 
3’-UTR of NCL mRNA.  TargetScan identified several miRNAs that could theoretically target 
NCL based on the presence of conserved sites in the 3’-UTR that matched the seed region of a 
miRNA (70).  Of the predicted targets, we selected miR-203a-3p for further study because of its 
previously defined role in skin development and reported downregulation in skin cancers (57, 58, 
59, 60).  
  
Figure 7.  MiR-203 downregulates NCL and targets the 3’-UTR.  (A-B) Western blot and Real-Time PCR 
analysis of NCL protein and mRNA in SKMEL-147 and SCC-13 48 h and 72 h (respectively) post-transfection 
with indicated amounts of miR-203.  (C) Capitals indicate the miR-203 binding site while red indicates the 
nucleotides removed from the NCL 3’-UTR to create psiCH-Ncl-MUT luciferase plasmid.  (D) SKMEL-147 cells 
were co-transfected with psiCH-Ncl-WT or psiCH-Ncl-MUT vectors and either control miRNA or miR-203 as 
indicated.  Ratio of luciferase to Renilla was measured 48 h post-transfection, ***p< 0.001.   
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First, we investigated the effect of increasing miR-203 levels on NCL in human melanoma 
and SCC cell lines.  SKMEL-147 and SCC-13 cells were transfected with 50 nM and 100 nM miR-
203, and the levels of NCL protein and mRNA were assessed via Western blot and Real-Time 
PCR after 48 or 72 h.  Fig. 7A-B shows reduced NCL protein and mRNA in miR-203 transfected 
cells in both cell lines.  From this, we concluded that miR-203 had an inhibitory effect on NCL 
protein and mRNA levels. 
 Since the 3’-UTR of NCL mRNA contains a miR-203 binding site, we hypothesized that 
miR-203 was having its inhibitory effect by directly targeting NCL mRNA through an interaction 
with the 3’-UTR.  To investigate this potential interaction, we utilized a luciferase reporter vector 
containing the 3’-UTR of NCL mRNA.  The whole 3’-UTR was cloned into the dual-luciferase 
psiCheck 2.0 vector at the 3’-end of the luciferase coding region (psiCH-Ncl-WT).  SKMEL-147 
cells were then co-transfected with this vector and either scrambled control miRNA (Sc) or miR-
203, and the ratio of firefly luciferase to Renilla was measured 48 h post-transfection.  
Additionally, to verify that the interaction of miR-203 and the NCL 3’-UTR was specific to the 
predicted miR-203 binding site, the binding site in the psiCH-Ncl-WT vector was removed through 
site directed mutagenesis to yield the psiCH-Ncl-MUT vector (Fig. 7C).  As shown in Fig. 7D, in 
cells containing the wild type vector and miR-203, reduced luciferase activity was observed.  
Conversely, in cells containing the mutant vector, no difference between Sc and miR-203 
transfected cells was seen.  These data support the conclusion that miR-203 inhibits NCL activity 
through a site specific interaction with its 3’-UTR. 
  
P53 regulates the expression of miR-203.  Previous reports have identified p53 as a positive 
regulator of miR-203 expression (61).  Based on these reports and the frequent loss or mutation of 
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p53 in SCC (17), we postulated that p53 regulates the expression of miR-203 in skin cancer.  First, 
we investigated the effects of exogenous p53 expression on miR-203.  To accomplish this, 
SKMEL-147 cells were transfected with a vector containing FLAG-tagged p53 (FLAG-p53).  P53 
protein levels were assessed by Western blot using an antibody against the FLAG tag while miR-
203 levels were assessed by Real-Time PCR 48 h after transfection. As shown in Fig. 8A, miR-
203 was expressed at higher levels in FLAG-p53 transfected cells compared to non-transfected 
controls. 
  
We also explored the effects of p53 upregulation on miR-203 levels in response to UVB-
induced DNA damage.  SKMEL-147 cells were exposed to 1 J/m2 of UVB radiation, and p53 
upregulation at the protein level was assessed by Western blot, 6 h post-UV exposure.  Effects on 
miR-203 levels were assessed using Real-Time PCR on total RNA extracts 6 h post-UV exposure.  
Figure 8.  P53 regulates miR-203.  (A)  SKMEL-147 cells were transfected with FLAG-p53.  P53 and miR-203 
levels were assessed by western blot and Real-Time PCR, respectively after 24 h.  (B)  MiR-203 levels in response 
to p53 activation by UVR were observed 6 h after SKMEL-147 cells were exposed to 1 J/m² UVB. (C)  SKMEL-
147 cells were transfected with the indicated concentrations of si-p53.  P53 downregulation and an increase in miR-





Fig. 8B shows how in response to UVB exposure p53 protein levels increased in treated cells, as 
previously described (61).  Notably, this upregulation was associated with an increase in miR-203 
levels.   
Additionally, we investigated the impact of p53 down-regulation on miR-203 expression.  
SKMEL-147 cells were transfected with 50 nM and 100 nM si-p53.  After 72 h, p53 protein levels 
and miR-203 expression were assessed via western blot and Real-Time PCR, respectively.  As 
shown in Fig. 8C, when p53 is decreased miR-203 expression is reduced. 
Taken together, these data indicate that p53 positively regulates miR-203 in skin cancer 
cells. 
 
4LB5 binds NCL on the surface of skin cancer cell lines.   
 
In cancer cells, NCL is frequently overexpressed resulting in oncogenic effects such as 
stabilization of BCL-2 and IL-2 mRNAs (71, 72).  Additionally, NCL localization to the cell 
surface is found in cancer cells but not their normal counterparts (73, 74, 75), making it an 
attractive candidate for therapeutically targeting cancer cells.  To this end, we have previously 
Figure 9.  4LB5 binds to the surface of melanoma cells.  (A) Cell ELISA performed on SKMEL-147 and NL-145 melanoma 
cells using the increasing concentrations of 4LB5 indicated, *p<0.05.  (B) SKMEL-147 cells were transfected with either siNCL 
or siControl (siC) RNA and ELISA was performed using 10nM of 4LB5, *p<0.05.  
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isolated 4LB5, a single chain variable fragment with high affinity for the RNA binding domains 
of NCL that demonstrated antineoplastic activity in breast cancer models (48).  To validate the use 
of 4LB5 as a tool for skin cancer therapy, we first confirmed that 4LB5 could bind NCL on the 
surface of melanoma cells.  In order for 4LB5 to have a therapeutic effect on skin cancer cells, the 
scFv must bind to surface NCL.  To assess binding, we performed a cell ELISA on SKMEL-147 
and NL-145 cells incubated with 50-200 nM 4LB5.  Fig. 9A shows that 4LB5 binding to both cell 
lines increased as the concentration of compound increased.  To confirm that this binding was 
specific to cell surface NCL, we repeated this ELISA in cells transfected with either a control 
silencing RNA (siC) or a NCL specific siRNA (siNCL).  Transfection with siNCL lowered total 
cellular NCL levels, consequently reducing surface NCL and resulting in reduced 4LB5 binding 
in these cells (Fig. 9B).  These data indicate 4LB5 binds to the surface of human and mouse 
melanoma cells through a specific interaction with NCL. 
 
4LB5 downregulates NCL-associated miRNAs in skin cancer. We have previously 
demonstrated that, once bound to surface NCL, 4LB5 can be internalized as NCL shuttles between 
Figure 10.  4LB5 downregulates miRNAs and impacts PTEN and pAKT levels.  (A) SKMEL-147 cells were 
treated with 100 nM of 4LB5 and RNA was extracted at 48 h.  Levels of miR-21, -221, and -222 were assessed 
by Real-Time PCR, ***p<0.001.  (B) SKMEL-147 cells were treated with 100 nM 4LB5.  At 48 h, proteins were 
extracted and levels of PTEN and pAKT were assessed via Western blot. 
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cellular compartments (48).  Internalized 4LB5 remains inside the cell where it continues to inhibit 
NCL (48).  In previous breast cancer studies, 4LB5 treatment was shown to lower the levels of 
NCL-associated miRNAs by disrupting the protein’s interaction with the miRNA (48), so we 
sought to investigate whether 4LB5 had similar effects in skin cancer.  When SKMEL-147 cells 
were treated with 100 nM of 4LB5, the levels of miR-21, -221, and -222 were all significantly 
downregulated at 72 h post-treatment (Fig. 10A), indicating that, also in human melanoma cells, 
4LB5 inhibits the NCL-dependent biogenesis of miR-21, -221, and -222. 
 Since NCL overexpression can lead to increased levels of miR-21, -221, and -222, we 
hypothesized that in cancer cells, this dysregulation leads to alterations in cellular pathways that 
allow cells to survive and proliferate.  Previous reports have shown that miR-221/-222 are a 
negative regulator of PTEN (76).  In normal cells, PTEN negatively regulates the activation of the 
AKT pathway, preventing excessive cellular proliferation (77, 78, 79), but in skin cancer, PTEN 
is frequently lost (80).  We sought to determine if treatment with 4LB5 could reverse the loss of 
PTEN by lowering the levels of miR-221/-222.  In SKMEL-147 cells treated with 100 nM of 4LB5 
for 48 h, PTEN protein was increased while AKT activation as measured by pAKT levels, was 
decreased (Fig. 10B) compared to non-treated cells. In summary, these results indicate that AKT 
activation can be, at least in part, reduced through upregulation of PTEN, by downregulating NCL-
dependent microRNAs via treatment with 4LB5. 
 
4LB5 inhibits cellular proliferation.  To determine whether the downregulation of NCL-
associated miRNAs and subsequent upregulation of PTEN was leading to reductions in 
proliferation, we assessed the effect of 4LB5 treatment on the proliferation of skin cancer cells.  
First, we performed an alamarBlue assay on SKMEL-147 cells treated with increasing 
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concentrations of 4LB5 (0-400 nM).  As shown in Fig. 11A, cellular proliferation decreased with 
higher treatment concentrations. 
Effects on proliferation were also assessed through colony assay.  SKMEL-147 and NL-
145 melanoma cells were plated at sub-confluent levels and treated with 10-100 nM 4LB5.  After 
72 h of treatment, media was changed and cells were allowed to grow for 7 days, at which point 
colony number was counted after crystal violet staining.  In both SKMEL-147 and NL-145 cells, 
proliferation compared to non-treated controls decreased significantly at the higher treatment 
concentrations (Fig. 11B).   
These observations indicate that 4LB5 inhibits cellular proliferation in both human and 






Figure 11.  4LB5 inhibits proliferation.  (A) SKMEL-147 cells were plated in 96-well plates and treated with the indicated increasing 
concentrations of 4LB5.  Proliferation was assessed by alamarBlue assay 48 h after treatment, *p<0.05; **p<0.01 compared to non-treated 
controls.  (B) Cells were plated in 6-well plates and treated with the indicated concentrations of 4LB5.  Colonies were stained with crystal 





Skin cancer represents a significant and growing burden on the health care system (1).  It 
is the most commonly diagnosed malignancy in the United States, and its incidence is expected to 
increase in the future due to rising exposure to UV radiation via sunlight (4).  Current treatment 
options for the most aggressive form, malignant melanoma, are limited and often ineffective in the 
later stages of the disease (6).  Thus, there is a need to design and develop new therapeutics.  NCL 
represents an attractive therapeutic target because of its cancer-cell specific localization to the 
plasma membrane and involvement in the biogenesis of oncogenic microRNAs (27, 34, 48). 
The mechanism of NCL upregulation in cancer cells is not well defined, but recent reports 
have provided evidence of regulation by miR-206, -194, and -494 in breast cancer (81, 82).  
Through computational target predictions, we identified that the NCL 3’-UTR also contained 
target sequences for miR-203 (70).  In SKMEL-147 and SCC-13 cells, exogenous expression of 
miR-203 led to significant decreases in NCL expression.  Since in transfected cells, decreases in 
NCL mRNA were observed, it is likely that this interaction causes reductions in NCL expression 
by destabilizing the mRNA rather than by affecting translation efficiency.  Luciferase reporter 
assays confirmed that miR-203 directly targets the 3’-UTR. 
MiR-203 expression is frequently lost in skin cancers, and its loss is associated with 
increased tumor aggressiveness and stage (57, 58, 59, 60).  Previous reports have linked miR-203 
expression with p53 expression (61), and we sought to verify this relationship in skin cancer cell 
lines.  In line with previous reports, exogenous expression of p53 in SKMEL-147 cells resulted in 
elevated miR-203 expression.  Additionally, activation of p53 in SKMEL-147 cells by exposure 
to UVB radiation led to increased miR-203 levels.  In contrast, transfection of these cells with a 
p53 silencing RNA resulted in miR-203 reduction.  The specific mechanism of interaction between 
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p53 and miR-203 is still unknown, and previous studies have failed to identify an interaction 
between the miR-203 promotor and p53 (83), implying that p53 may influence miR-203 
expression through an indirect pathway.  
Taken together, our results support a pathway from DNA damage to increased NCL 
expression via p53 and miR-203.  As depicted in Fig. 12A, in response to DNA damage, p53 
expression and activation increases resulting in higher levels of miR-203 through a yet to be 
identified mechanism.  Increased expression of miR-203 destabilizes NCL mRNA and prevents 
overexpression of the protein, thus preventing the overexpression of oncogenic miRNAs.  
However, in cells with mutated or abrogated p53, miR-203 upregulation is not accomplished and 
NCL expression increases unchecked. 
Since NCL is overexpressed and present on the cell surface of skin cancer cells, we sought 
to determine whether NCL targeting was a viable strategy for skin cancer treatment.  Previously, 
we developed 4LB5, a scFv targeted to the 4 RNA binding domains of NCL, to target cell surface 
NCL (48).  In breast cancer, we demonstrated that the antineoplastic effects of 4LB5 were 
achieved, at least in part, through the downregulation of three oncogenic miRNAs, miR-21, -221, 
and -222 (48).  In melanoma cell lines, 4LB5 bound specifically to cell surface NCL and this 
binding led to significant reductions in miR-21, -221, and -222.  Since these miRNAs are negative 
regulators of PTEN, which is commonly lost in skin cancers, we evaluated the effects of 4LB5 
treatment on PTEN and its downstream target, AKT.  In response to treatment, PTEN levels in 
SKMEL-147 cells were increased while the activation of AKT, as measured by pAKT levels, were 
decreased.  Additionally, as shown by colony and alamarBlue assays, the proliferation of treated 
SKMEL-147 and NL-145 cells was significantly reduced.  These data support 4LB5 as a promising 
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tool for skin cancer treatment and NCL targeting as a valid approach in the development of cancer 
therapeutics. 
Overall, we propose that when 
p53 is lost or mutated, cells lose one of 
the mechanisms responsible for NCL 
regulation, resulting in an 
overexpression of this protein (Fig. 
12B).  Overexpression of NCL leads to 
higher levels of miR-21, -221, and -222 
which alter the functions of numerous 
pathways.  In one of these pathways, 
PTEN expression is suppressed 
allowing for the hyper-activation of 
AKT, leading to increased cellular 
proliferation and contributing to the 
development of skin cancers.  However, with 4LB5, we can target this pathway downstream of the 
initial mutation to restore PTEN expression and inhibit proliferation.   
Future investigation of the effects of miR-203 expression on the cellular localization of 
NCL is required to determine if miR-203 could be a marker for 4LB5 sensitivity in skin cancers.  
Since the mechanism of miR-203 regulation by p53 is still unknown, studies should also focus on 
this area.  Association studies in melanoma patients between p53 mutations and NCL 
overexpression, as well as expression levels of miR-21, -221, -222, and -203 could offer additional 
insights into the mechanism of NCL regulation in skin cancer.  In summary, we have identified 
Figure 12.  Regulation of NCL in response to DNA damage.  (A) In 
normal cells, DNA damage due to UVB results in the upregulation of p53 
which increases the expression miR-203.  This miRNA inhibits NCL and 
prevents its overexpression.  (B) In cells with lost or mutated p53, miR-
203 is not upregulated in response to DNA damage and NCL is over 
expressed leading to an increase in miR-221/-222 which allows the cell to 
survive and proliferate by inhibiting PTEN and hyper-activating the AKT 
pathway.  Treatment with 4LB5 combats NCL over-expression by 
preventing the biogenesis of miR-221/-222 allowing increased PTEN 
expression and lower proliferation. 
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and described a potential pathway of NCL overexpression in skin cancer cells and demonstrated 
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